Renibus Therapeutics(R), a US-based clinical-stage biotech company focusing on the prevention and treatment of cardio-renal diseases, announced on Wednesday that company management will participate in the 22nd Annual Needham Virtual Healthcare Conference, taking place virtually from 17-20 April 2023.

Frank Stonebanks, Renibus' co-CEO, will present a company overview on Wednesday, 19 April 2023 at 11:45 ET. Renibus management will also participate in one-on-one meetings with investors during the conference.

Renibus said that it has developed a robust portfolio of products that activate multiple cytoprotective pathways, including organ protection via preconditioning. Renibus' first-in-class lead program, RBT-1 (stannic protoporfin/iron sucrose), is a potent inducer of anti-inflammatory and antioxidant pathways. RBT-1 has finished its Phase 2 development in cardiac surgery and will soon enter a Phase 3 registration study for its lead indication to reduce the risk of postoperative complications following cardiothoracic surgery.